Showing results (161-170 of 427) with videos related to

Sort By:
Pageof 43
Annals of Hematology|June 7, 2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practiceEmilia Scalzulli, Matteo Molica, Danilo Alunni Fegatelli, et al.
Expert Opinion on Drug Safety|June 14, 2024
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safetyAlessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna, et al.
Leukemia & Lymphoma|March 16, 2021
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experienceSara Pepe, Emilia Scalzulli, Gioia Colafigli, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 22, 2005
Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemiasMaria José Carnicer, Sergio Bernardini, Lorenza Bellincampi, et al.
Frontiers in Oncology|March 24, 2025
Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitalsFrancesca Palandri, Alessandro Inzoli, Antonella Barone, et al.
Frontiers in Oncology|January 24, 2024
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case reportSilvio Ligia, Emilia Scalzulli, Ida Carmosino, et al.
Annals of Hematology|May 10, 2012
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient populationMassimo Breccia, Paola Finsinger, Giuseppina Loglisci, et al.
Oncotarget|February 28, 2018
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinibMassimo Breccia, Matteo Molica, Gioia Colafigli, et al.
Leukemia & Lymphoma|June 1, 2012
Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experienceMassimo Breccia, Paola Finsinger, Giuseppina Loglisci, et al.
Critical Reviews in Oncology/Hematology|November 9, 2016
Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontlineMassimo Breccia, Eleonora Arboscello, Andrea Bellodi, et al.
Pageof 43